Jan 29 (Reuters) - Prometic Life Sciences Inc:
* PROMETIC‘S PBI-4050: PHASE 3 PIVOTAL CLINICAL TRIAL DESIGN FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) FINALIZED
* PROMETIC LIFE SCIENCES - BASED ON RECOMMENDATIONS FROM FDA, CO NOW WILL UNDERTAKE AN “ALL COMERS STUDY”
* PROMETIC - PBI-4050 STUDY WILL ENROLL PATIENTS WITH MILD-TO-MODERATE IPF, REGARDLESS OF BACKGROUND STANDARD OF CARE WITH NINTEDANIB OR NOT Source text for Eikon: Further company coverage:
 